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Abstract 
Background: Artemisinin‑based combination therapy (ACT) has been adopted by the World Health Organization as 
a first‑line treatment for uncomplicated Plasmodium falciparum malaria. In endemic regions, it has proven more effec‑
tive in treating the disease, and even in reducing its transmission. Nonetheless, there is a scarcity of studies carried out 
in non‑endemic areas on imported uncomplicated malaria.
Methods: This is a retrospective, observational study performed on patients diagnosed and admitted with uncompli‑
cated P. falciparum malaria between 2004 and 2015. The objective was to compare the parasite clearance period and 
the average hospital length of stay for patients treated with ACT vs those receiving other treatment regimens.
Results: Eighty‑five patients were included in the study. Fifty‑one received ACT treatment (dihydroartemisinin–
piperaquine) and thirty‑four patients were treated with quinine sulfate+doxycycline or atovaquone/proguanil. The 
parasite clearance period was shorter in the group of patients treated with ACT compared to those receiving other 
treatment types: 24 h (IQR 24) vs 48 h (IQR 48), p < 0.01. The average hospital stay was also shorter in the ACT group 
with respect to the second group: 2.67 days (IQR 1.08) vs 3.96 days (IQR 2.87), p < 0.001. A mild case of hepatitis was 
registered in the group treated with ACT.
Conclusions: ACT treatment of admitted hospital patients with imported uncomplicated malaria from P. falciparum 
reduced the days spent hospitalized as well as producing a more rapid parasite clearance compared to classic treat‑
ment. In spite of being treated with safe medications, one has to be alert to possible adverse effects such as hepatitis 
and delayed haemolytic anaemia.
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Background
Malaria is the most important parasitic disease world-
wide. It has been calculated that each year is it respon-
sible for new episodes in around 214 million patients, 
causing the death of approximately 438,000 the majority 
of which are children under 5 years of age and pregnant 
women [1, 2], not to mention incalculable economic 
loss in endemic countries. In Europe, apart from iso-
lated cases in Greece, malaria continues to be exclusively 
imported, with approximately 11,000 cases reported 
each year, making it the most important tropical disease 
on this continent [3–6]. Most imported malaria cases 
(as many as 88–98  %) are diagnosed in recently-arrived 
immigrants or resident immigrants who return to their 
country of origin to visit friends or family visiting friends 
and relatives (VFR); sub-Saharan Africa being the region 
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from which most cases originate. Eighty percent of 
declared imported cases of malaria in Europe are P. fal-
ciparum [3–5].
Malaria treatment has changed substantially over 
recent years [7]. Artesunate has proven to be superior 
to quinine in most situations where complicated malaria 
is treated [8–12]. In uncomplicated malaria, regimens 
known as artemisinin-based combination therapy (ACT) 
demonstrates greater efficacy in treating the disease, 
reducing transmission in endemic areas and produc-
ing lower levels of reinfection [13–17]. For this reason, 
artemisinin derivatives are currently recommended as 
first-line medication for P. falciparum malaria treatment, 
whether complicated (severe) or uncomplicated, both in 
endemic and non-endemic countries [18–20].
Artemisinin treatment leads to a reduction in average 
hospital stays, more rapid parasite clearance in compari-
son with any other anti-malarial [11, 12, 17]; and, in com-
plicated malaria, a lowering of the global mortality rate 
[8, 9]. The majority of these studies have been carried out 
in endemic areas. In non-endemic countries, in patients 
with complicated malaria, treatment with artesunate 
additionally reduced the days spent in intensive care 
units (ICU) [11, 12]. However, in patients with uncom-
plicated malaria from P. falciparum, there are few studies 
comparing the differences in non-endemic regions [17].
This study aims to analyse the impact that the use of 
ACT has had compared to two classic treatments (qui-
nine sulfate and doxycycline/clindamycin or atovaquone-
proguanil) to treat patients admitted with uncomplicated 
malaria from P. falciparum to a hospital in a non-endemic 
area.
Methods
A retrospective observational study was carried out on all 
patients admitted with malaria to Hospital Poniente (El 
Ejido, Almería. Spain) from January 2004 to December 
2015. The hospital serves a population of approximately 
250,000 people, in an area with a large African immigrant 
population, many of whom work in horticultural green-
houses. The study included patients over 14 years of age 
whose reason for hospital admission was exclusively the 
diagnosis of uncomplicated malaria from P. falciparum 
[19]. Pregnant women and HIV patients were excluded 
from the study. The disease was diagnosed using direct 
thin and thick smear microscopy in tandem with a rapid 
diagnostic test (SD Bioline malaria Ag Pf/Pan®) using 
lateral flow assays. The malarial PCR (semi-nested mul-
tiplex PCR) was used only in cases where a more precise 
confirmation was needed of the species, or where there 
was a suspicion of mixed parasitic infection. A clinical 
history and complete physical examination were carried 
out on all patients, gathering epidemiological and clinical 
data. On admission, screening was performed for the 
most prevalent imported pathologies; this included HIV, 
HBV  and  HCV  blood tests. Parasitaemia monitoring 
was carried out via a daily smear until a negative result 
was obtained. After leaving hospital, the patients were 
checked with a blood test and a blood smear at 7 and 
28 days.
Uncomplicated malaria is defined following the rec-
ommendations for the management of imported malaria 
in Europe [19]. With regard to parasitaemia, patients 
who came from endemic countries (semi-immune 
patients) were considered uncomplicated if they had a 
parasitaemia level of <5 and <2 % in non-immune indi-
viduals. Dihydroartemisinin–piperaquine (Eurartesim® 
320  mg/40  mg, Sigma Tau) was the ACT chosen; this 
medication is currently the commercial form available in 
Spain.
Variables were analysed corresponding to epidemio-
logical, clinical and analytical characteristics as well as 
the parasite clearance period and the average hospital 
stay. The level of parasitaemia was divided into patients 
with <1 %, between 1 and 2 %, and >2–5 %. Any possible 
adverse secondary effects associated with the treatment 
were also recorded.
Data were analysed using the statistical software pack-
age SPSS v17. A descriptive analysis was carried out on 
the quantitative variables using the mean and the stand-
ard deviation, as well as the range. Qualitative variables 
were described using absolute frequencies and percent-
ages. To observe the possible differences between the 
group of patients treated with quinine and doxycycline/
clindamycin or atovaquone–proguanil and ACT, the 
Pearson’s Chi square test or Fisher’s exact test was used 
when the variables were qualitative. When the variables 
for comparison were quantitative, the mean differences 
were estimated using the Student’s t test for independent 
samples if they complied with the normal hypothesis and 
the Mann–Whitney U test when they did not.
A multivariate linear regression model was performed 
using days of hospitalization as the dependent variable 
and the treatment group, the haemoglobin (Hb) and 
platelet levels (at the time of diagnosis) and the level of 
parasitaemia as the independent variables. The good-
ness-of-fit was calculated along with the determination 
coefficient. For all tests, the fixed level of significance was 
0.05. This study was approved by the local ethic commit-
tee (Almería, Spain) with code 12/2016.
Results
A total of 85 patients diagnosed with uncompli-
cated malaria were included in the study. The phar-
maceuticals used for malaria treatment were quinine 
sulfate+doxycycline or atovaquone/proguanil until 
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2012. In the same year, dihydroartemisinin–pipe-
raquine was introduced, remaining as the first-line treat-
ment since then. Fifty-one patients were treated with 
dihydroartemisinin–piperaquine and 34 with quinine 
sulfate+doxycycline (n  =  33) or atovaquone/proguanil 
(n =  1). The dataset supporting the conclusions of this 
study is included as Additional file 1.
The general patient characteristics, both together and 
by groups, are shown in Table  1. The average age was 
32  years (IQR 9), 96.5  % of which were male (n =  82). 
All of the patients except one (a Spanish expatriate) 
originated from sub-Saharan Africa, and 94.1  % were 
treated as VFR patients. No differences were observed 
on admittance between the study groups with relation 
to age, gender, country of origin, type of traveler, or 
basal Hb and platelet levels, nor the level of parasitae-
mia. Regarding concomitant diseases, one patient was 
diabetic (in the quinine sulfate+doxycycline group), 
two presented with arterial hypertension (in the qui-
nine sulfate+doxycycline group), and ten patients pre-
sented with chronic hepatitis B (five in the quinine 
sulfate+doxycycline group and five in the dihydroarte-
misinin–piperaquine group).
The global parasite clearance time was 24  h (IQR 24) 
and the average hospital stay was 2.88 days (IQR 1.88). In 
the subgroup analysis, the parasite clearance time was 
significantly less in the patient group treated with ACT 
rather than the classic treatment: 24  h (IQR 24) vs 48  h 
(IQR 48), p  <  0.01. The average stay was also less in the 
artemisinin group with respect to the group treated with 
quinine+doxycycline/atovaquone-proguanil: 2.67  days 
(IQR 1.08) vs 3.96 days (IQR 2.87), p < 0.001 (Table 1; Fig. 1).
With regard to the Hb levels during the follow-up at 7 
and 28  days, patients treated with dihydroartemisinin–
piperaquine presented higher levels on both occasions 
(ACT group vs quinine+doxycycline/atovaquone-pro-
guanil: day 7: 13.37 g/dL ± 1.48 (range 10–16) vs 12.65 g/
dL  ±  1.42 (range 10–15.5), p  =  0.03; day 28: 14.32  g/
dL ±  1.2 (range 11.7–16.8) vs 13.45 g/dL ±  1.38 (range 
9.1–14.8), p = 0.02.
In the lineal regression model (Table  2), the vari-
ables showing an influence on the average days of 
Table 1 Characteristics of the patients included in the study
a In the group of patients treated with quinine sulphate, the average parasite clearance time was determined in 16 patients. In the remainder (n = 18) daily smears 
were not carried out. The variables gender, origin, type of traveller, haemoglobin (basal levels, 7 and 28 days) and parasitaemia level follow a normal distribution. The 
quantitative variables that do not follow a normal distribution pattern are age, platelets, length of hospital stay and parasite clearance time






 (IQR) 32 (9) 31.5 (8) 33 (10) 0.99
Gender
 Male 82 (96.5 %) 32 (94.1 %) 50 (98 %) 0.56
 Female 3 (3.5 %) 2 (5.9 %) 1 (2 %)
Origin
 Sub‑Saharan Africa 84 (98.8 %) 34 (100 %) 50 (98 %) 0.49
 Spain 1 (1.2 %) 0 1 (2 %)
Type of traveller
 VFR 80 (94.1 %) 31 (91.2 %) 49 (96 %) 0.25
 Recent arrival 4 (4.7 %) 3 (8.8 %) 1 (2 %)
 Expatriate 1 (1.2 %) 0 1 (2 %)
Hb on admission (g/dL) ± typical deviation 
(range)
13.7 ± 1.5 (10.1–16.9) 13.5 ± 1.5 (10.1–16.9) 13.8 ± 1.4 (10.1–16.4) 0.36
Hb day 7 (g/dL) ± typical deviation (range) 13.08 ± 1.49 (10–16) 12.65 ± 1.42 (10–15.5) 13.37 ± 1.48 (10–16) 0.03
Hb day 28 (g/dL) ± typical deviation (range) 13.94 ± 1.34 (9.1–16.8) 13.45 ± 1.38 (9.1–14.8) 14.32 ± 1.2 (11.7–16.8) 0.02
Total platelets ×103/µL; median (IQR) 94 (60) 93 (59) 95 (81) 0.93
Parasitaemia level (%)
 <1 48 (56.5 %) 18 (52.9 %) 30 (58.8 %) 0.22
 1–2 26 (30.6 %) 9 (26.5 %) 17 (33.3 %)
 >2–5 11 (12.9 %) 7 (20.6 %) 4 (7.8 %)
Time in which parasitaemia becomes nega‑
tive. Hours; median (IQR)a
24 (24) 48 (48) 24 (24) <0.01
Period of hospitalization. Days; median (IQR) 2.88 (1.88) 3.96 (2.87) 2.67 (1.08) <0.001
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hospitalization were the Hb and platelet levels at the time 
of admission and whether there was elevated parasitae-
mia (>2–5 %). The variable with the greatest association 
power was the treatment group, with a typified coef-
ficient of −0.409. For the same Hb, platelet and parasi-
taemia levels, the use of ACT resulted in a reduction in 
hospital stay of almost a day and a half (−1.35 days).
With regard to any reported adverse effects, in the 
group treated with dihydroartemisinin–piperaquine, 
there was one mild case of hepatitis, in the only non-sub-
Saharan patient; this was self-limiting but, nevertheless, 
led to more days spent in hospital (6 days).
Discussion
ACT is a very effective and safe treatment in the manage-
ment of imported uncomplicated malaria. Besides pro-
ducing more rapid parasite clearance, its use in patients 
admitted with uncomplicated malaria reduces the period 
of hospitalization compared to classic treatments that 
were used previously, resulting in healthcare savings.
The management of imported malaria is still a challenge 
for many healthcare professionals in non-endemic zones. 
P. falciparum is the species most frequently involved, 
and also the one which most results in morbidity and/
or mortality in travellers (tourists and expatriates), as 
well as in foreigners who return home to visit friends and 
family [3–5]. The use of artemisinin derivatives has been 
spreading, various articles have been published showing 
the superior results of these drugs compared to other 
treatments; indeed, their use has been recommended as 
a first-line drug in the main national and international 
guidelines [18–20]. Quinine is now relegated to a second-
line treatment for cases where contraindications exist, or 
because of the unavailability of ACT or atovaquone–pro-
guanil; likewise in complicated malaria treatment given 
within the first trimester of pregnancy due to the possi-
bility of teratogenicity [7, 18–20].
Most studies concerning imported malaria have been 
carried out on patients with complicated malaria [11, 12] 
with artesunate being the most-commonly used drug for 
intravenous treatment. Besides producing faster parasite 
clearance and ending fever, it has a better safety profile 
(posing predominantly less risk of severe hypoglycae-
mia), shortens hospitalization and has recently been 
shown to reduce the length of time in ICU, above all in 
patients with more elevated parasitaemia [12]. No reduc-
tion in mortality has been demonstrated given the few 
patients who died in the studies thus making such analy-
sis impossible, although with the solid evidence obtained 
in endemic regions, it would be unethical to carry out 
clinical trials with this objective in mind.
In the case of uncomplicated malaria caused by P. fal-
ciparum, the general recommendation is hospital admit-
tance and oral treatment for at least 24–48 h [20], with 
the aim of observing the clinical evolution and tolerance 
to the drugs. Very few studies have been carried out with 
ACT in non-endemic zones. Hatz et  al. [21] concluded 
that treatment with artemether–lumefantrine is safe and 







Fig. 1 Days of hospitalization per treatment group
Table 2 Linear regression model
ACT artemisinin‑based combination therapy
R2 = 0.404 (p < 0.001). The model we have constructed explains 40.4 % of the variability in the average hospital stay. The variables that influence the average stay are 
the type of treatment, Hb, platelets and having elevated parasitaemia. The variable with the greatest power of association is the treatment type, which has a typified 
coefficient of 0.409. For the same level of Hb, platelets or parasitaemia, the use of ACT results in almost 1 day less of hospitalization (−1.35 days)
Coefficient Typified coefficient
B Typical error Beta Significance
Treatment with quinine/atovaquone–proguanil or ACT −1.349 0.293 −0.409 <0.001
Hb on admission 0.314 0.097 0.284 <0.01
Platelets on admission −0.007 0.002 −0.258 <0.01
Average parasitaemia −0.009 0.319 −0.003 0.98
High parasitaemia 1.083 0.449 0.225 0.02
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multicentre study (MALTHER) compared the various 
treatment regimens for imported uncomplicated malaria 
in Europe [17]. There were a total of 18 different regi-
mens although the most used were atovaquone–progua-
nil, quinine and artemether–lumefantrine. Compared to 
other regimens, quinine was associated with the highest 
non-completion rate, more secondary effects and the 
most days of hospitalization. In contrast, the artemether–
mefloquine combination was linked to the fastest para-
site clearance and cessation of fever. Regarding the period 
of hospitalization, the use of quinine was associated with 
longer hospital stays. In this study, unlike the MALTHER 
study, dihydroartemisinin–piperaquine was used as the 
ACT, the only drug of its type commercially available in 
Spain and presumably the main drug used in the major-
ity of Spanish hospitals; this combination has also been 
demonstrated to be efficacious and safe both in endemic 
countries as well as in Europe [16, 22]. In addition, as 
belonging to just one centre, the two groups of patients 
compared were much more homogenous thus avoid-
ing, to a large extent, any bias derived from variations in 
clinical practice between healthcare sites or in different 
countries.
The overall average hospital stay for patients in our 
study was 2.88 days. The fact that most of the patients are 
immigrants has probably contributed to a slightly longer 
stay to that recommended. The language barrier that 
exists with many of these patients, as well as the prob-
lems concerning frequent follow-up visits to the health-
care centres, often for economic or work-related reasons, 
means that it is common their doctors feel more com-
fortable keeping them admitted to hospital until they are 
sure of good treatment tolerance and response. The rapid 
parasite clearance and the markedly shorter treatment 
regimen using ACT are probably the factors that most 
influence the length of stay.
Atovaquone–proguanil is another medication rec-
ommended as a first-line treatment for uncomplicated 
malaria from P. falciparum [18–20]; however, the parasite 
clearance rate is longer than with ACT and the adverse 
effects, above all gastrointestinal, are similarly more fre-
quent [17]. Furthermore, ACT has a very good profile in 
relation to possible Plasmodium resistance.
With regard to possible adverse reactions, the com-
pounds derived from artemisinin have shown good tol-
erance and have a good safety profile [23, 24]. The most 
frequent adverse effects are: Type 1 hypersensitivity at 
the cutaneous level; a long QTc interval in the ECG; and, 
at the gastrointestinal level, nausea, vomiting and diar-
rhoea, although often this can be clinically confused with 
the malaria itself [25]. Cases have also been described 
of raised  transaminase  levels or hepatitis. This was 
only observed in one patient; and although there were 
no important consequences and the condition ceased 
after only a few days, it did result in more days spent in 
hospital.
The most severe adverse effect of artemisinin derivatives 
however is delayed haemolytic anaemia [25–28]. This is 
produced by the “pitting” mechanism, in which the para-
sitized erythrocytes, after being cleared of parasites by the 
spleen, are resealed and returned to the blood stream, but 
with a reduced lifespan of 1–3 weeks [28]. This lysis pro-
cess occurs on average 2 weeks after the drug is adminis-
tered, and in some cases can require a blood transfusion. 
Although this has mainly been seen in patients with com-
plicated malaria (with elevated parasitaemia) treated with 
artesunate, it has also been described in patients treated 
with intramuscular artemether and oral artemether–
lumefantrine [27]. As far as it is known, no case has been 
reported in relation to dihydroartemisinin–piperaquine. 
In this study, the Hb levels were higher even in the group 
treated with ACT at 7 and 28  days. This is probably 
because in patients with uncomplicated malaria, delayed 
haemolysis is the exception; in fact, the more rapidly the 
parasitaemia disappears and the ACT-treated patients 
recover, the more rapid the accompanying recovery of the 
basal hemoglobin levels as well.
With regard to pregnancy, there is insufficient infor-
mation about the safety and efficacy of many anti-malar-
ials, especially in the first trimester. Consequently, the 
only drugs considered safe are quinine, chloroquine, 
clindamycin and proguanil. Artemisinin-derived drugs 
are safe and efficacious in the second and third trimes-
ters, in that they have been demonstrated not to be tera-
togenic [29, 30].
The limitations present in this study come from the fact 
that it is a retrospective work.
Furthermore, given the characteristics of the popula-
tion that is the object of the study, the results may only be 
strictly extrapolated to African immigrants treated with 
two treatment regimens, one which has already passed 
to second-line use (quinine sulfate–doxycycline) and the 
other, an ACT (dihydroartemisinin–piperaquine), which 
is a first-line treatment. New prospective studies will 
need to be carried out to evaluate if any differences exist 
in terms of safety, efficacy and healthcare costs between 
the ACT-based treatments and, for example, atovaquone–
proguanil, which is also a fixed combination over the same 
period (3  days in total). Moreover, with atovaquone–
proguanil, ample experience has been gathered in non-
endemic regions and it has a proven safety record.
Conclusions
The results of this work reinforce the results of the few 
studies published to date regarding ACT treatments for 
patients with uncomplicated malaria in non-endemic 
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regions. They are drugs with a good safety record, clear-
ing parasitaemia more rapidly than other anti-malarials, 
and are probably more cost effective by reducing the 
average length of stay in hospital. Nonetheless, despite 
being safe drugs, one should be alert to the possibility of 
adverse effects such as hepatitis and delayed haemolytic 
anaemia.
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